Explore

Trendline Trendline
Arrowhead Pharmaceuticals to Engage in Key Healthcare Conferences in June 2026

Arrowhead Pharmaceuticals to Engage in Key Healthcare Conferences in June 2026

Arrowhead Pharmaceuticals to Engage in Key Healthcare Conferences in June 2026
Trendline Trendline
Charles River Laboratories to Present Strategic Focus at Major Conferences

Charles River Laboratories to Present Strategic Focus at Major Conferences

Charles River Laboratories to Present Strategic Focus at Major Conferences
Trendline Trendline
Contineum Therapeutics to Present at Goldman Sachs Global Healthcare Conference

Contineum Therapeutics to Present at Goldman Sachs Global Healthcare Conference

Contineum Therapeutics to Present at Goldman Sachs Global Healthcare Conference
Trendline Trendline
Contineum Therapeutics to Present at 2026 Goldman Sachs Global Healthcare Conference

Contineum Therapeutics to Present at 2026 Goldman Sachs Global Healthcare Conference

Contineum Therapeutics to Present at 2026 Goldman Sachs Global Healthcare Conference
Trendline Trendline
Charles River Laboratories to Present at Major Conferences

Charles River Laboratories to Present at Major Conferences

Charles River Laboratories to Present at Major Conferences
Trendline Trendline
Seaport Therapeutics to Engage in Key Investor Conferences Amidst Neuropsychiatric Drug Development

Seaport Therapeutics to Engage in Key Investor Conferences Amidst Neuropsychiatric Drug Development

Seaport Therapeutics to Engage in Key Investor Conferences Amidst Neuropsychiatric Drug Development
Trendline Trendline
Eli Lilly Partners with Ascidian Therapeutics for $1.9 Billion RNA Exon Editing Deal Targeting Kidney Diseases

Eli Lilly Partners with Ascidian Therapeutics for $1.9 Billion RNA Exon Editing Deal Targeting Kidney Diseases

Eli Lilly Partners with Ascidian Therapeutics for $1.9 Billion RNA Exon Editing Deal Targeting Kidney Diseases
Trendline Trendline
Eli Lilly Partners with Haisco in $3 Billion Deal for Early-Stage Drug Development

Eli Lilly Partners with Haisco in $3 Billion Deal for Early-Stage Drug Development

Eli Lilly Partners with Haisco in $3 Billion Deal for Early-Stage Drug Development
Trendline Trendline
Corsair Pharma Reports Positive Phase 1 Results for TRX-248 Transdermal System in PAH Treatment

Corsair Pharma Reports Positive Phase 1 Results for TRX-248 Transdermal System in PAH Treatment

Corsair Pharma Reports Positive Phase 1 Results for TRX-248 Transdermal System in PAH Treatment
Trendline Trendline
Circio and GenAssist Partner to Develop Gene Therapy for Muscle Disease

Circio and GenAssist Partner to Develop Gene Therapy for Muscle Disease

Circio and GenAssist Partner to Develop Gene Therapy for Muscle Disease
Trendline Trendline
Pfizer's Phase 3 Trials Highlighted at ASCO 2026

Pfizer's Phase 3 Trials Highlighted at ASCO 2026

Pfizer's Phase 3 Trials Highlighted at ASCO 2026
Trendline Trendline
Lysoway Therapeutics Secures Grant from Michael J. Fox Foundation to Advance Parkinson's Disease Treatment

Lysoway Therapeutics Secures Grant from Michael J. Fox Foundation to Advance Parkinson's Disease Treatment

Lysoway Therapeutics Secures Grant from Michael J. Fox Foundation to Advance Parkinson's Disease Treatment